JP2018509398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509398A5 JP2018509398A5 JP2017543934A JP2017543934A JP2018509398A5 JP 2018509398 A5 JP2018509398 A5 JP 2018509398A5 JP 2017543934 A JP2017543934 A JP 2017543934A JP 2017543934 A JP2017543934 A JP 2017543934A JP 2018509398 A5 JP2018509398 A5 JP 2018509398A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- mosm
- formulation
- inh
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims description 8
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims description 8
- 150000008575 L-amino acids Chemical class 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010019860 Hereditary angioedema Diseases 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 206010030113 Oedema Diseases 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 239000008176 lyophilized powder Substances 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 2
- 229940038773 trisodium citrate Drugs 0.000 claims 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 102000002397 Kinins Human genes 0.000 claims 1
- 108010093008 Kinins Proteins 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229930003836 cresol Natural products 0.000 claims 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 208000021822 hypotensive Diseases 0.000 claims 1
- 230000001077 hypotensive effect Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 238000002324 minimally invasive surgery Methods 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 229940074404 sodium succinate Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15156010.9 | 2015-02-20 | ||
| EP15156010 | 2015-02-20 | ||
| PCT/EP2016/053559 WO2016131958A1 (en) | 2015-02-20 | 2016-02-19 | Pharmaceutical formulations of c1 esterase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509398A JP2018509398A (ja) | 2018-04-05 |
| JP2018509398A5 true JP2018509398A5 (cg-RX-API-DMAC7.html) | 2019-04-11 |
| JP6516855B2 JP6516855B2 (ja) | 2019-05-22 |
Family
ID=52573617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543934A Expired - Fee Related JP6516855B2 (ja) | 2015-02-20 | 2016-02-19 | Ｃ１エステラーゼ阻害剤の医薬製剤 |
Country Status (13)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562149A (zh) | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
| WO2018210944A1 (en) * | 2017-05-16 | 2018-11-22 | Octapharma Ag | C1-esterase inhibitor preparation |
| CN120381522A (zh) * | 2025-04-02 | 2025-07-29 | 南方医科大学南方医院 | 一种治疗肝硬化门脉高压的化合物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2758076B1 (en) * | 2011-09-24 | 2018-12-12 | CSL Behring GmbH | Combination therapy using immunoglobulin and c1-inhibitor |
| EP3290046B1 (en) * | 2013-03-15 | 2019-01-02 | Shire Viropharma Incorporated | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |
-
2016
- 2016-02-19 AU AU2016221627A patent/AU2016221627A1/en not_active Abandoned
- 2016-02-19 RU RU2017132449A patent/RU2017132449A/ru not_active Application Discontinuation
- 2016-02-19 EP EP16705521.9A patent/EP3258911A1/en not_active Withdrawn
- 2016-02-19 WO PCT/EP2016/053559 patent/WO2016131958A1/en not_active Ceased
- 2016-02-19 SG SG11201706019XA patent/SG11201706019XA/en unknown
- 2016-02-19 BR BR112017017685A patent/BR112017017685A2/pt not_active Application Discontinuation
- 2016-02-19 KR KR1020177026457A patent/KR20170118856A/ko not_active Withdrawn
- 2016-02-19 JP JP2017543934A patent/JP6516855B2/ja not_active Expired - Fee Related
- 2016-02-19 CA CA2977090A patent/CA2977090A1/en not_active Abandoned
- 2016-02-19 US US15/551,256 patent/US20180036394A1/en not_active Abandoned
- 2016-02-19 MX MX2017010323A patent/MX2017010323A/es unknown
- 2016-02-19 CN CN201680010988.7A patent/CN107257683A/zh active Pending
-
2017
- 2017-08-03 IL IL253824A patent/IL253824A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7042531B2 (ja) | デオキシコール酸を含む医薬組成物 | |
| JP7455402B2 (ja) | マグネシウム含有オキシトシン製剤および使用の方法 | |
| JP2022116191A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| US20250195439A1 (en) | Method for treating local lesion disease | |
| AU2014232912A1 (en) | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency | |
| JP5684954B1 (ja) | 安定性を改善したロクロニウム製剤 | |
| WO2020240514A1 (en) | Stable formulations of indocyanine green | |
| CN104918619A (zh) | 稳定的肠胃外dnj组合物 | |
| RU2350323C2 (ru) | Способ кардиопротекции и нейропротекции внутривенным введением галогенсодержащего летучего анестезирующего средства | |
| JP2018509398A5 (cg-RX-API-DMAC7.html) | ||
| TW201716056A (zh) | 藥學組成物 | |
| BR112020002325A2 (pt) | composições farmacêuticas | |
| RU2017132449A (ru) | Фармацевтические композиции ингибитора c1-эстеразы | |
| JP2021535197A (ja) | 疣贅の治療 | |
| AU2025205070A1 (en) | Treatment Of Patients With Severe Von Willebrand Disease Undergoing Elective Surgery By Administration Of Recombinant VWF | |
| US11554156B2 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| US20070197442A1 (en) | Methods for the Treatment of Macular Degeneration and Related Eye Conditions | |
| US20140107130A1 (en) | Oral Solution Formulations of Aripiprazole | |
| JP7184792B2 (ja) | 変形性関節症の治療のための組成物 | |
| JP7752425B2 (ja) | ２，２，６，６－テトラメチル－１－ピペリジニルオキシルの揮発使用による細胞死抑制と組織保護 | |
| RU2817638C2 (ru) | Способ лечения хронической ишемии нижних конечностей II и III степени атеросклеротического генеза при окклюзирующих поражениях аорто-бедренного сегмента | |
| KR20230160261A (ko) | 급성 허혈성 뇌졸중을 치료하는 dc009 | |
| CA3063183A1 (en) | Use of peptide compounds in treating acute pancreatitis | |
| US10588945B2 (en) | Agent for preventing onset of idiopathic osteonecrosis of femoral head and/or suppressing progress of same | |
| CA3213365A1 (en) | Prevention and treatment of coronavirus infection |